Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $13.60.

Several analysts recently issued reports on OBIO shares. Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday, March 12th. Wall Street Zen cut Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings cut Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. B. Riley Financial cut their target price on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, Barclays raised their target price on Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th.

Insider Buying and Selling at Orchestra BioMed

In other news, insider David P. Hochman acquired 10,000 shares of the business’s stock in a transaction on Friday, March 13th. The shares were acquired at an average cost of $4.29 per share, with a total value of $42,900.00. Following the transaction, the insider owned 1,086,467 shares in the company, valued at $4,660,943.43. The trade was a 0.93% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Eric S. Fain acquired 20,000 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were purchased at an average cost of $4.13 per share, for a total transaction of $82,600.00. Following the completion of the transaction, the director owned 91,709 shares in the company, valued at approximately $378,758.17. This represents a 27.89% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 44,636 shares of company stock valued at $181,831. 7.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Orchestra BioMed

Several large investors have recently bought and sold shares of OBIO. China Universal Asset Management Co. Ltd. bought a new stake in Orchestra BioMed during the 4th quarter valued at approximately $38,000. Creative Planning purchased a new position in shares of Orchestra BioMed during the second quarter valued at approximately $40,000. XTX Topco Ltd purchased a new position in shares of Orchestra BioMed during the second quarter valued at approximately $45,000. Jane Street Group LLC purchased a new position in shares of Orchestra BioMed during the second quarter valued at approximately $50,000. Finally, Virtu Financial LLC purchased a new position in shares of Orchestra BioMed during the fourth quarter valued at approximately $57,000. 53.20% of the stock is owned by institutional investors.

Orchestra BioMed Stock Down 2.0%

NASDAQ OBIO opened at $3.83 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 7.03 and a quick ratio of 7.01. The stock has a market capitalization of $229.34 million, a PE ratio of -3.95 and a beta of 0.51. Orchestra BioMed has a 1 year low of $2.20 and a 1 year high of $5.42. The business’s 50-day moving average is $4.18 and its 200 day moving average is $4.28.

Orchestra BioMed (NASDAQ:OBIO) last posted its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.07. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.92 million. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%. Sell-side analysts forecast that Orchestra BioMed will post -1.47 earnings per share for the current year.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.